Orexin-A
Also known as: Orexin A, Hypocretin-1, Hcrt-1, OXA, Hypocretin 1
Not approved as a drug anywhere; research peptide only. Approved orexin-system drugs are small molecules (antagonists for insomnia; OX2R agonist oveporexton for narcolepsy type 1, FDA August 2026).
5 notable studies · 10 references
TLDR
Orexin-A (hypocretin-1) is a 33-amino-acid hypothalamic neuropeptide that acts on both orexin receptors and is central to keeping wakefulness stable; its loss causes narcolepsy type 1. The biology is very well established, but direct use of orexin-A in humans has been tested only in small intranasal pilot studies, and no orexin-A product is approved. The approved orexin-targeting drugs are small molecules: sleep-promoting receptor blockers and, since August 2026, the OX2R agonist oveporexton for narcolepsy type 1.
At a Glance
Classification: Endogenous 33-amino-acid hypothalamic neuropeptide; prepro-orexin (HCRT gene) product; dual orexin-receptor (OX1R/OX2R) agonist neuropeptide
Orexin-A is one of two neuropeptides made by a small cluster of neurons in the lateral hypothalamus. It was discovered in 1998 by two groups at nearly the same time, which is why it carries two names: "orexin-A" (from the Greek for appetite) and "hypocretin-1." Orexin-A is 33 amino acids long, held in shape by two internal disulfide bridges, with a pyroglutamyl N-terminus and an amidated C-terminus. Its sibling, Orexin-B, is cut from the same precursor protein. Orexin-A is studied mainly for: • Wakefulness and sleep–wake stability • Narcolepsy type 1 • REM sleep regulation • Feeding and energy balance • Sympathetic and cardiovascular control • Reward and motivation circuits. Its most solid claim to fame is narcolepsy. People with narcolepsy with cataplexy usually have very low or undetectable orexin-A (hypocretin-1) in their cerebrospinal fluid, and post-mortem studies show loss of orexin peptides in their brains. That is the biology. Using orexin-A itself as a treatment is a different story: human administration studies are small pilot trials of intranasal orexin-A, and no orexin-A product is approved anywhere.
What Is Orexin-A?
Orexin-A is an endogenous neuropeptide, not a synthetic designer peptide. The HCRT gene encodes prepro-orexin ↓ prepro-orexin is cleaved ↓ orexin-A (33 aa, two disulfide bonds) + orexin-B (28 aa, linear). Orexin-A binds both known orexin receptors: • OX1R (orexin receptor 1, HCRTR1) • OX2R (orexin receptor 2, HCRTR2). It has high affinity for both, while orexin-B is clearly preferred only by OX2R. That makes orexin-A the "dual" signal of the system. The orexin neurons themselves number only in the tens of thousands in humans, but they project widely through the brain, to arousal centers such as the locus coeruleus (noradrenaline), tuberomammillary nucleus (histamine), raphe nuclei (serotonin) and cholinergic and dopaminergic groups.
What Are Researchers Studying?
Narcolepsy type 1
Narcolepsy with cataplexy is the clearest human orexin-deficiency state. Early work showed hypocretin was undetectable in the cerebrospinal fluid of most people with narcolepsy, and post-mortem brains showed a generalized absence of hypocretin peptides. This led to the idea of replacing the missing signal. Direct peptide replacement has been tested only in small pilot studies; the more successful approach has been small-molecule OX2R agonists.
REM sleep stability
In small placebo-controlled crossover studies of people with narcolepsy with cataplexy, intranasal orexin-A reduced REM sleep amount and reduced direct wake-to-REM transitions. These are interesting physiological signals, not proof of clinical benefit.
Cognition under sleep deprivation
In rhesus monkeys deprived of sleep for 30–36 hours, orexin-A given intravenously or as a nasal spray improved performance on a hard delayed match-to-sample task, with matching changes in brain glucose metabolism. Alert, rested animals were largely unaffected. This is a primate finding, not evidence that orexin-A offsets sleep loss in people.
Feeding and energy balance
The original 1998 discovery paper reported that orexins injected into the brain increased food intake in rats, and fasting raised prepro-orexin expression. Later work suggests orexin's role in feeding is tied to arousal and motivation as much as appetite itself.
Autonomic and cardiovascular control
In a small pilot in 10 healthy men, intranasal orexin-A increased muscle sympathetic nerve activity compared with placebo, without changing blood pressure or heart rate over the test period. This fits animal data linking orexin to sympathetic tone.
Olfaction
People with narcolepsy with cataplexy scored lower on smell tests than matched controls, and intranasal orexin-A improved odor detection thresholds in a small crossover study.
How Does It Work?
Orexin-A ↓ binds OX1R and OX2R (G protein-coupled receptors) ↓ mostly excitatory signaling (Gq-linked calcium signaling in many neurons) ↓ increased firing of monoaminergic and cholinergic arousal neurons ↓ consolidated wakefulness, suppression of inappropriate REM sleep, and support of motivated behaviors such as feeding. Loss of orexin signaling does not simply make animals or people "sleepier." It destabilizes the boundaries between states, which is why narcolepsy features abrupt sleep attacks, sleep-onset REM periods and cataplexy (sudden muscle weakness triggered by emotion). One practical problem for using orexin-A as a drug: as a peptide it crosses the blood–brain barrier poorly. Researchers have tried intravenous and intranasal routes in animals and intranasal delivery in small human studies. The pharmaceutical field has largely moved to small-molecule orexin receptor agonists instead. The OX2R agonist oveporexton (TAK-861) was FDA-approved in August 2026 for narcolepsy type 1.
What Does the Research Show?
Human research
Biology / diagnostics — HIGH. The link between orexin deficiency and narcolepsy with cataplexy is among the best-established facts in sleep medicine. Low cerebrospinal-fluid hypocretin-1 is a recognized diagnostic marker for narcolepsy type 1. Administration of orexin-A — LOW. Human administration data are limited to small, mostly crossover pilot studies of intranasal orexin-A (roughly 7–14 participants each), mainly in narcolepsy with cataplexy, plus one pilot in 10 healthy men. Effects were measurable but modest (REM sleep stabilization, fewer wake-to-REM transitions, improved smell thresholds, changes in sympathetic nerve activity). None of this establishes a treatment.
Animal research
EXTENSIVE. Knockout mice, canine narcolepsy genetics, central infusion studies and primate work all support orexin's role in arousal. In sleep-deprived rhesus monkeys, intravenous and intranasal orexin-A improved performance on a demanding memory task.
In-vitro research
EXTENSIVE. Receptor pharmacology, signaling and structure of the orexin system are well characterized.
Notable Studies
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior
in-vitroJournal: Cell. Discovery paper. The authors identified orexin-A and orexin-B as ligands for two orphan G protein-coupled receptors (OX1R and OX2R), described their hypothalamic expression, and reported increased food intake after central administration in rats.
Limitations: Foundational discovery work. Feeding effects came from brain injection in rodents; the paper does not address therapeutic use.
View publication →Hypocretin (orexin) deficiency in human narcolepsy
humanJournal: Lancet. Cerebrospinal-fluid hypocretin-1 was undetectable in seven of nine people with narcolepsy, linking human narcolepsy to loss of orexin signaling.
Limitations: Very small sample and a short research letter. Measures the body's own peptide; it says nothing about giving orexin-A as a treatment.
View publication →Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates
animalJournal: Journal of Neuroscience. In sleep-deprived rhesus monkeys, intravenous and intranasal orexin-A improved performance on a high-load delayed match-to-sample task, and nasal delivery outperformed the intravenous route. Brain glucose-metabolism changes tracked the behavioral effect.
Limitations: Small number of animals, a single task, and short-term administration. Primate results do not establish human cognitive effects or safety.
View publication →Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy
humanJournal: Sleep Medicine. Double-blind, placebo-controlled crossover pilot in 8 people with narcolepsy with cataplexy. Intranasal orexin-A before night sleep did not significantly change nocturnal wakefulness but reduced REM sleep (especially later in the night) and reduced direct wake-to-REM transitions.
Limitations: Eight participants, a single night, and physiological endpoints only. No daytime sleepiness or long-term outcomes.
View publication →The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy
humanJournal: Behavioural Brain Research. Placebo-controlled crossover study in 14 people with narcolepsy with cataplexy. Morning intranasal orexin-A was followed by fewer wake-to-REM transitions, less REM sleep, and fewer errors on a divided-attention test.
Limitations: Small, single-dose design from the same research group as Study 4. Effects on daytime sleepiness were not clearly established, and nothing is known about repeated use.
View publication →What We Still Don't Know
• How much intranasal orexin-A actually reaches relevant brain regions in humans • Whether repeated peptide administration produces durable clinical benefit • Long-term safety of exogenous orexin-A in humans • Cardiovascular effects of sustained orexin receptor stimulation • Effects in people without orexin deficiency • Whether peptide replacement offers anything that small-molecule OX2R agonists do not • The precise contribution of OX1R versus OX2R to each effect • Independent replication of the intranasal human studies outside the original German research group.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Orexin-A research with you.
Get the Aminodex Orexin-A Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–585.
- de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95(1):322–327.
- Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39–40.
- Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991–997.
- Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci. 2007;27(52):14239–14247.
- Baier PC, Weinhold SL, Huth V, et al. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain. 2008;131(Pt 10):2734–2741.
- Baier PC, Hallschmid M, Seeck-Hirschner M, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12(10):941–946.
- Weinhold SL, Seeck-Hirschner M, Nowak A, et al. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res. 2014;262:8–13.
- Meusel M, Voß J, Krapalis A, et al. Intranasal orexin A modulates sympathetic vascular tone: a pilot study in healthy male humans. J Neurophysiol. 2022;127(2):548–558.
- U.S. Food and Drug Administration. FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms (oveporexton). 2026.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.